Treasury Blacklists More Folks: Hands Off Their U.S. Cash
Published Date: 8/26/2025
Notice
Summary
The U.S. Treasury’s OFAC just added new people to its blacklist, meaning their money and property in the U.S. are frozen. Americans can’t do business with these folks anymore. This move helps keep bad actors out of the U.S. financial system, and it’s effective immediately.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
New OFAC SDN Listings Freeze Assets
The Treasury’s OFAC added one or more people to the Specially Designated Nationals and Blocked Persons (SDN) List. All of those persons’ property and interests in property subject to U.S. jurisdiction are blocked, and U.S. persons are generally prohibited from engaging in transactions with them. This action is effective immediately.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20525, Notice of OFAC Sanctions Action
The U.S. Treasury’s OFAC just blocked the property of Faouzi Barika and others linked to Hamas, making it illegal for Americans to do business with them. This action, effective October 2, 2026, freezes their assets under U.S. law to stop support for terrorism. If you’re a U.S. person, watch out—any dealings with these folks are off-limits and could have serious consequences.
2026-20526, Notice of OFAC Sanctions Actions
The U.S. Treasury’s OFAC just updated its sanctions lists by unblocking some people and removing their names from the banned list. They also cleaned up duplicate entries and updated info on others who remain blocked. These changes affect individuals and entities tied to sanctions, with some unblocked as of July 27, 2026, meaning their assets are no longer frozen.
2026-20425, Notice of OFAC Sanctions Action
The U.S. Treasury’s OFAC just blocked the property of Rafael Buenrostro Martin and others for their roles in illegal drug trade and terrorism. From September 29, 2026, Americans can’t do business with these folks, freezing their assets under U.S. law. This move aims to cut off their money flow and stop bad activities fast and firmly.
2026-20475, Notice of OFAC Sanctions Action
On October 1, 2026, the U.S. Treasury’s OFAC added new individuals and companies to its blacklist, freezing their U.S.-based assets. This means Americans can’t do business with these blocked parties, cutting off their access to U.S. money and markets. The move aims to tighten financial controls and protect U.S. interests.
2026-20395, Notice of OFAC Sanctions Action
The U.S. Treasury’s OFAC just blocked all property linked to A7 NETWORK, a criminal group operating in Russia, Kyrgyzstan, Nigeria, and Zimbabwe. This means Americans can’t do business with them anymore, effective October 1, 2026. It’s a big move to stop shady international crime and protect U.S. interests.
2026-20215, Notice of OFAC Sanctions Action
The U.S. Treasury’s OFAC just added new people to its blacklist, meaning their U.S.-based money and property are frozen. Americans can’t do business with these folks anymore, starting September 29, 2026. This move aims to stop bad actors from using the U.S. financial system and sends a clear message: no funny business allowed!
Previous / Next Documents
Previous: 2025-16226, National Human Genome Research Institute; Amended Notice of Meeting
The National Human Genome Research Institute changed the meeting time for its advisory council on September 16, 2025. The meeting now starts at 9:30 a.m. and ends at 2:30 p.m., instead of the original 9:00 a.m. to 1:00 p.m. This update affects anyone interested in attending or following the meeting, with no changes to costs or location.
Next: 2025-16265, Determination of Regulatory Review Period for Purposes of Patent Extension; IQIRVO
The FDA has officially set the review period for IQIRVO, a human drug product, so its patent can be extended. This helps the company behind IQIRVO get extra time to protect their invention after going through the FDA’s approval process. If you’re involved in drug patents or development, this means important deadlines and opportunities to keep an invention exclusive just got clearer.